ITGA4 and inflammatory bowel disease: This finding is particularly important considering the mechanism of action of vedolizumab and etrolizumab, which target the α4β7 integrin heterodimer (encoded by ITGA4 and ITGB7) to modulate gut-selective immune responses in IBD treatment (De Lange et al., 2017).